BioNxt Advances MS Treatment with Innovative Dissolvable Film Drug Delivery

BioNxt Solutions Inc. (OTCQB: BNXTF) has completed a comparative pharmacokinetic (PK) study of its oral dissolvable film (ODF) based proprietary Cladribine product for the treatment of Multiple Sclerosis (MS).

BioNxt is developing a proprietary hybrid-generic ODF Cladribine dosage form for the MS market. In February 2023, the company reported positive results from a preclinical oral toxicity study of ODF Cladribine. The company stated it will report results from its PK study as they become available.

Highlights

BioNxt’s study was conducted by a European contract research organization in accordance with EU medical regulatory guidelines using animal models and a single administration of either sublingual or oral (tablet) Cladribine.

Cladribine tablets are approved for use in over 75 countries, including by the FDA and the European Medicines Agency, for several indications.

Approximately 2.3 million people are living with MS worldwide, with the highest prevalence in North America and Europe. The global MS drug market is expected to top $41 billion by 2033 according to Market.us. 

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.